This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Xinlay
Description: Xinlay, formerly known as atrasentan, belongs to a group of compounds called Selective Endothelin-A Antagonists (SERA). It inhibits endothelin, a protein that promotes cancer cell growth and bone metastasis.
Additional information available to subscribers only: